Volume 6.46 | Nov 27

Cord Blood News 6.46 November 27, 2014
Cord Blood News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  CBN on Twitter
Plasma CC-Chemokine Ligand 28 Level Is Correlated with Hematopoietic Stem Cells in Human Cord Blood
To reveal the effect of CC-chemokine ligand 28 (CCL28) on hematopoietic cells in human cord blood (CB) at birth, researchers measured CCL28 in frozen CB plasma, which was preserved as a reference sample for cryopreserved CB units for hematopoietic stem cells transplantation. [Transfusion] Abstract
Learn more: StemSpan™ Megakaryocyte Expansion Supplement
PUBLICATIONS (Ranked by impact factor of the journal)
Striatal Transplantation of Human Dopaminergic Neurons Differentiated from Induced Pluripotent Stem Cells Derived from Umbilical Cord Blood Using Lentiviral Reprogramming
Human cord blood-derived induced pluripotent stem cells were differentiated into dopaminergic neurons utilizing two different in vitro protocols for neural induction: by fibroblast growth factor signaling, by bone morphogenetic protein/transforming growth factor inhibition. [Cell Transplant] Full Article

MSCs Conditioned Media and Umbilical Cord Blood Plasma Metabolomics and Composition
Researchers investigated the detailed composition of human umbilical cord blood plasma and conditioned medium by 1H-NMR and Multiplexing LASER Bead Technology. [PLoS One] Full Article

IL-6 Secreted from Senescent Mesenchymal Stem Cells Promotes Proliferation and Migration of Breast Cancer Cells
By establishing senescent human umbilical cord mesenchymal stem cells (s-UCMSCs) through the replicative senescence model and genotoxic stress induced premature senescence model, scientists show that s-UCMSCs significantly stimulate proliferation and migration of breast cancer cells in vitro and tumor progression in a co-transplant xenograft mouse model compared with ‘young’ counterparts. [PLoS One] Full Article

Secretome of Mesenchymal Progenitors from the Umbilical Cord Acts as Modulator of Neural/Glial Proliferation and Differentiation
Investigators assessed whether the secretome of human umbilical cord perivascular cells is able to induce the differentiation of human telencephalon neural precursor cells in vitro, and modulate neural/glial proliferation, differentiation and survival in the dentate gyrus of adult rat hippocampus. [Stem Cell Rev] Abstract

Impact of Very Early CD4+/CD8+ T Cell Counts on the Occurrence of Acute Graft-versus-Host Disease and NK Cell Counts on Outcome after Pediatric Allogeneic Hematopoietic Stem Cell Transplantation
The authors retrospectively analyzed very early lymphocyte subset counts following transplantation from their five-year pediatric allogeneic hematopoietic stem cell transplantation (HSCT) material to find clinically relevant associations with post transplant outcome, and the major complication of HSCT, acute graft-versus-host disease. They analyzed HSCTs performed due to acute leukemias and lymphomas from matched unrelated donors, unrelated cord blood and matched sibling donors. [Pediatr Blood Cancer] Abstract

AKT Pathway Affects Bone Regeneration in Nonunion Treated with Umbilical Cord-Derived Mesenchymal Stem Cells
Investigators applied an established human umbilical cord-derived mesenchymal stem cells-treated rat nonunion model with the addition of an inhibitor of AKT. [Cell Biochem Biophys] Abstract | Full Article

MSCs with ACE II Gene Affect Apoptosis Pathway of Acute Lung Injury Induced by Bleomycin
Researchers evaluated the effect and related mechanisms of mesenchymal stem cells (MSCs) and Angiotensin converting enzyme II (ACE II) on acute lung injury. MSCs were separated from umbilical cord cells, and the changes of phenotype before and after ACE II silence were observed using flow cytometry. [Exp Lung Res] Abstract

Umbilical Cord-Derived Mesenchymal Stem Cell Therapy for Neurological Disorders via Inhibition of Mitogen-Activated Protein Kinase Pathway-Mediated Apoptosis
100 patients who underwent subarachnoid placement of umbilical cord-derived mesenchymal stem cells were included in this study. Investigators evaluated the number of attempts, localization of subarachnoid space and postprocedural complications. [Mol Med Rep] Abstract

Use TeSR-E7 to generate iPS cells with high quality colony morphology for easy identification and rapid subcloning. Request your sample.
(Lymph)angiogenic Influences on Hematopoietic Cells in Acute Myeloid Leukemia
The authors note the importance of lymphangiogenic factors and their receptors in hematopoietic cells in acute myeloid leukemia (AML). Understanding the functional characterization of (lymph)angiogenic factors in the bone marrow niche in AML will also be helpful in interrupting the engraftment of leukemic stem cells and for enhancing immune cell function by modulating the tumor microenvironment. [Exp Mol Med] Full Article

Visit our reviews page to see a complete list of reviews in the cord blood research field.

Don't miss ASGCT 18th Annual Meeting!
Juno T Cell Therapy for Leukemia Granted FDA Breakthrough Therapy Designation
Juno Therapeutics announced that the FDA has granted Breakthrough Therapy Designation to the company’s JCAR015 chimeric antigen receptor product candidate. The designation applies for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia and was filed by Juno’s collaboration partner, Memorial Sloan Kettering Cancer Center, where Phase I clinical trials are currently underway. [Juno Therapeutics Inc.]
Press Release

BerGenBio Receives Orphan-Drug Designation from FDA for BGB324 in the Treatment of Acute Myeloid Leukemia
BerGenBio AS announced that the US Food and Drug Administration (FDA) has granted orphan-drug designation for BGB324 for treatment of acute myeloid leukemia (AML). Earlier BerGenBio announced that the first patient has been dosed in its multi-center Phase Ib trial of BGB324, a selective inhibitor of Axl, in patients with AML. [BerGenBio AS] Press Release

From our sponsor: Free mouse hematopoietic progenitors wallchart. Request your copy.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW EMBO | EMBL Symposium: Frontiers in Stem Cells & Cancer
March 29-31, 2015
Heidelberg, Germany

Visit our events page to see a complete list of events in the cord blood community.
NEW Mesenchymal Stem Cell (MSC) Laboratory Technician (California Cryobank)

NEW Clinical Laboratory Scientist – Umbilical Cord Blood Processing (California Cryobank)

PhD Student – Department of Hematopoiesis (Sanquin)

Head of Cellular and Molecular Therapies Laboratory (NHS Blood & Transplant)

Postdoctoral Fellow – Stem Cell Biology Gene Expression and Regulation (The University of Texas Medical School at Houston)

Postdoctoral Fellow – Molecular Mechanisms Regulating Human Hematopoietic Specification (Washington University School of Medicine)

Quality Improvement Coordinator – Regenerative Medicine (The University of Texas Health Science Center at Houston)

Cord Tissue Processing Technician (Cord Blood Registry)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Cord Blood News: Archives | Events | Contact Us